secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001140361-23-029848
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma enters separation agreement with former CEO Sooch; $1.18M in lump sums
--------------------------------------------------------------------------------

- $678,756 lump sum (base salary + pro rata bonus) plus $500,000 second lump sum after 6 months.
- Stock options vest through April 19, 2024; exercisable until later of original expiration or April 19, 2026.
- Restricted stock units vest as if employed through April 19, 2024.
- Health insurance premiums paid for 12 months post-separation, subject to no other coverage.
- Agreement includes non-competition, non-solicitation, mutual release and non-disparagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123029848/0001140361-23-029848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123029848/brhc20054327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-029848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer